S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64
10.14309/01.ajg.0000773052.38150.f9